My 3D animation on Moderna’s vaccine candidate. Editorial use only.
Moderna reported that its coronavirus vaccine candidate was found to be safe and produced a strong immune response in older adults in its Phase 1 trial with participants aged 18 to 55, and then in a final analysis of 20 adults aged 56 to 70 and over. The immune response was similar in these age groups. The data indicates that older adults are found to have antibody levels two to three times higher than that found in patients who have recovered from Covid-19. These results are encouraging as it was not clear whether the vaccine would be able to protect both younger and older adults.
Moderna’s study have not yet been peer-reviewed or published in a scientific journal, but the company said it has submitted the results to a peer-reviewed publication.
Related Posts
